These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9572544)

  • 41. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H; Takamura T; Nagai Y; Kaneko S;
    J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
    Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
    Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
    Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
    J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prefeeding of aldose reductase inhibitor inhibits galactose cataract].
    Tsuji T; Okamoto S; Ikebe H; Terubayashi H; Akagi Y; Tanimoto T
    Nippon Ganka Gakkai Zasshi; 1993 Apr; 97(4):455-9. PubMed ID: 8317365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
    Iso K; Tada H; Kuboki K; Inokuchi T
    J Diabetes Complications; 2001; 15(5):241-4. PubMed ID: 11522497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF; Inoue J; Secchi EF; Lizak MJ; Rodriguez L; Mori K; Greentree W; Blessing K; Lackner PA; Sato S
    Exp Eye Res; 1998 Aug; 67(2):203-8. PubMed ID: 9733586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The inhibitory effect of aldose reductase inhibitor for proliferation in the lens epithelial cells of rat sugar cataract].
    Morikubo S; Takamura Y; Kubo E; Tsuzuki S; Akagi Y
    Nippon Ganka Gakkai Zasshi; 2003 Oct; 107(10):565-70. PubMed ID: 14598706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs.
    Kador PF; Takahashi Y; Akagi Y; Blessing K; Randazzo J; Wyman M
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):63-9. PubMed ID: 17341153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Restoration of nitric oxide production by aldose reductase inhibitor in human endothelial cells cultured in high-glucose medium.
    Okuda Y; Kawashima K; Suzuki S; Asakura Y; Asano M; Tsurumaru K; Dai H; Tachi Y; Bannai C; Saitoh M; Yamashita K
    Life Sci; 1997; 60(3):PL53-6. PubMed ID: 9000650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
    Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
    Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
    Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
    Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of an aldose reductase inhibitor on altered sympathetic nerve responsiveness of isolated right atria in diabetic rats.
    Sato N; Hashimoto H; Takiguchi Y; Nakashima M
    Arzneimittelforschung; 1990 Jul; 40(7):763-6. PubMed ID: 2121149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathy].
    Kojima K; Matsubara H; Mizuno K; Harada T; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Nippon Ganka Gakkai Zasshi; 1985 Feb; 89(2):247-56. PubMed ID: 3923790
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
    Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
    Gu J; Wang JJ; Yan J; Cui CF; Wu WH; Li L; Wang ZS; Yu M; Gao N; Liu L; Ouyang DS
    J Ethnopharmacol; 2011 Jan; 133(1):6-13. PubMed ID: 20817083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ciliary body changes associate with aldose reductase in galactosemic rats].
    Ikebe H; Terubayashi H; Akagi Y; Kador PF; Kinoshita JH
    Nippon Ganka Gakkai Zasshi; 1989 Jul; 93(7):758-62. PubMed ID: 2514592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition in rat of development of in utero galactose-induced cataract by an aldose reductase inhibitor--a light microscopic study.
    Teshima R; Taura T; Okamura R
    Jpn J Ophthalmol; 1991; 35(3):317-24. PubMed ID: 1770672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
    Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
    Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.